Lexaria Bioscience Corp.
LEXX
$0.60
$0.034.44%
NASDAQ
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.44% | 17.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.46% | -40.59% | |||
| Operating Income | 7.73% | 36.42% | |||
| Income Before Tax | 9.12% | 40.84% | |||
| Income Tax Expenses | 44.44% | -- | |||
| Earnings from Continuing Operations | 9.06% | 40.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 12.00% | 78.57% | |||
| Net Income | 9.09% | 40.83% | |||
| EBIT | 7.73% | 36.42% | |||
| EBITDA | 7.97% | 36.55% | |||
| EPS Basic | 20.51% | 45.82% | |||
| Normalized Basic EPS | 19.39% | 41.75% | |||
| EPS Diluted | 20.51% | 45.82% | |||
| Normalized Diluted EPS | 19.39% | 41.75% | |||
| Average Basic Shares Outstanding | 14.35% | 9.19% | |||
| Average Diluted Shares Outstanding | 14.35% | 9.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||